Global AI, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Global AI, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $24.9K | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | $34.0K | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | $49.0K | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $60.0K | Feb 8, 2024 |
| FY2017 | Sep 30, 2017 | $67.5K | Dec 29, 2017 |
| FY2017 | Sep 30, 2016 | $40.8K | Dec 29, 2017 |
| FY2016 | Sep 30, 2015 | $45.4K | Dec 12, 2016 |
| FY2015 | Sep 30, 2014 | $71.0K | Dec 23, 2015 |
| FY2014 | Sep 30, 2013 | $60.5K | Dec 24, 2014 |
| FY2013 | Sep 30, 2012 | $73.9K | Jan 13, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $24.9K | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | $49.0K | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $60.0K | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | $72.5K | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | $79.5K | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $90.3K | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $56.0K | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | $67.5K | Dec 28, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.6K | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | $34.0K | Jun 16, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.00M) | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | ($637.4K) | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | ($116.1K) | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $758 | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | ($4.9K) | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | $12.8K | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $23.3K | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | ($19.3K) | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | $4.2K | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | ($37.5K) | Dec 29, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.00M) | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | ($635.6K) | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | ($113.3K) | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $4.5K | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | ($1.2K) | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | $16.5K | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $27.7K | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | ($14.8K) | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | ($11.9K) | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | ($54.3K) | Dec 29, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $44.3K | Jun 16, 2025 |
| FY2021 | Sep 30, 2020 | $625 | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $620 | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $1.4K | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | $550 | Dec 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($927.4K) | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | ($325.1K) | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | ($5.8K) | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $2.0K | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | ($8.2K) | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | ($491) | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $26.9K | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | ($7.7K) | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | ($7.4K) | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | ($50.3K) | Dec 29, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $39.1K | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | $185.1K | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | $1.1K | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $16.5K | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | $11.7K | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | $15.0K | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $9.0K | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $7.9K | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | $15.1K | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | $422 | Dec 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $338.9K | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | $237.2K | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | $29.1K | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | $102.6K | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | $98.7K | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | $96.9K | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | $103.7K | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $126.0K | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | $114.0K | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | $103.5K | Dec 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($299.9K) | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | ($52.1K) | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | ($28.0K) | Feb 8, 2024 |
| FY2024 | Dec 31, 2022 | ($89.0K) | Jun 16, 2025 |
| FY2023 | Sep 30, 2022 | ($86.2K) | Feb 8, 2024 |
| FY2023 | Sep 30, 2021 | ($86.9K) | Feb 8, 2024 |
| FY2022 | Sep 30, 2020 | ($82.0K) | Dec 19, 2022 |
| FY2021 | Sep 30, 2019 | ($94.8K) | Dec 20, 2021 |
| FY2020 | Sep 30, 2018 | ($118.1K) | Nov 12, 2020 |
| FY2019 | Sep 30, 2017 | ($98.8K) | Nov 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.05M) | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | ($2.05M) | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | ($1.53M) | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | ($1.41M) | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | ($1.41M) | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | ($1.41M) | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | ($1.42M) | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | ($1.44M) | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | ($1.42M) | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | ($1.43M) | Dec 29, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Dec 19, 2022 |
| FY2019 | Sep 30, 2019 | 0 | Nov 1, 2019 |
| FY2019 | Sep 30, 2018 | 0 | Nov 1, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 8, 2024 |
| FY2019 | Sep 30, 2019 | 0 | Nov 1, 2019 |
| FY2019 | Sep 30, 2018 | 0 | Nov 1, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 154.35M | Jun 16, 2025 |
| FY2024 | Dec 31, 2023 | 154.35M | Jun 16, 2025 |
| FY2023 | Sep 30, 2023 | 28.58M | Feb 8, 2024 |
| FY2023 | Sep 30, 2022 | 26.92M | Feb 8, 2024 |
| FY2022 | Sep 30, 2021 | 26.92M | Dec 19, 2022 |
| FY2021 | Sep 30, 2020 | 26.92M | Dec 20, 2021 |
| FY2020 | Sep 30, 2019 | 26.92M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | 26.92M | Nov 1, 2019 |
| FY2018 | Sep 30, 2017 | 26.92M | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | 26.92M | Dec 29, 2017 |